Consistent with recent studies utilizing BET inhibition (27), these observations suggest that the utilization of BET inhibitors/degraders in sequence with Fulvestrant + Palbociclib may provide a therapeutic advantage for breast cancer patients undergoing standard of care therapy. Here, DNER is linked to breast carcinoma.